Touyun Biotech Group Limited Fundamental Analysis (HKSE: 1332.HK)
Touyun Biotech Group Limited Fundamental Analysis (HKSE: 1332.HK)
Touyun Biotech Group Limited (HKSE: 1332.HK) shows weak financial fundamentals with a PE ratio of 34.88, profit margin of 40.02%, and ROE of -46.63%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 1332.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1332.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1332.HK shows balanced valuation metrics.
Growth Score
Weak1332.HK faces weak or negative growth trends.
Financial Health Score
Moderate1332.HK shows balanced financial health with some risks.
Profitability Score
Weak1332.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1332.HK Expensive or Cheap?
P/E Ratio
1332.HK trades at 34.88 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1332.HK's PEG of 0.10 indicates potential undervaluation.
Price to Book
The market values Touyun Biotech Group Limited at -16.33 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.26 times EBITDA. This is generally considered low.
How Well Does 1332.HK Make Money?
Net Profit Margin
For every $100 in sales, Touyun Biotech Group Limited keeps $40.02 as profit after all expenses.
Operating Margin
Core operations generate -89.81 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-46.63 in profit for every $100 of shareholder equity.
ROA
Touyun Biotech Group Limited generates $4.32 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Touyun Biotech Group Limited generates limited operating cash flow of $-14.94M, signaling weaker underlying cash strength.
Free Cash Flow
Touyun Biotech Group Limited generates weak or negative free cash flow of $-16.44M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
1332.HK converts -7.75% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
34.88
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
-16.33
vs 25 benchmark
P/S Ratio
Price to sales ratio
6.28
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-8.09
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.17
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.47
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
-2.13
vs 25 benchmark
How 1332.HK Stacks Against Its Sector Peers
| Metric | 1332.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 34.88 | 25.50 | Worse (Expensive) |
| ROE | -46.63% | 964.00% | Weak |
| Net Margin | 40.02% | -4901.00% (disorted) | Strong |
| Debt/Equity | -8.09 | 0.60 | Strong (Low Leverage) |
| Current Ratio | 0.17 | 2.34 | Weak Liquidity |
| ROA | 4.32% | 322.00% | Weak |
1332.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Touyun Biotech Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
EPS CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary
FCF CAGR
N/A
Industry Style: Cyclical, Growth, Discretionary